STAT
NOVEMBER 10, 2023
Pharmacies were once abundant in the South Side of Chicago. Now, residents living in the majority Black neighborhood often find themselves with few options when it’s time to get a prescription refilled or stock up on cold medicine. Ladell Johnson, a longtime resident of the South Side, drives half an hour from her house to the downtown area every time she needs to pick up her prescription.
ALiEM - Pharm Pearls
NOVEMBER 10, 2023
A 33-year-old male presented to the emergency department with a diffuse pruritic rash that appeared several days after starting Trimethoprim/Sulfamethoxazole (TMP-SMX) for a dental infection. Initially beginning on the torso and low back, the rash spread to the palms, soles, and genitalia. Progression stopped after discontinuing TMP-SMX. He conveyed a remote history of a similar rash following use of an unknown medication, and noted that several of the current lesions arose at the same location
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
NOVEMBER 10, 2023
An expert panel that advises the United Kingdom on vaccine policy has recommended using a meningitis B vaccine to try to bring down spiking rates of gonorrhea. If adopted, the U.K. would be the first country to use the meningitis B vaccine for this purpose. The Joint Committee on Vaccination and Immunization released a report Friday saying that targeted use of a meningitis B vaccine — GSK’s Bexsero — in people at high risk of contracting gonorrhea should reduce the inci
PharmaVoice
NOVEMBER 10, 2023
As revenue growth remained high last year, so did biopharma CEO pay in the U.S.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
NOVEMBER 10, 2023
Luz (not her real name) could be a great doctor. A Latina student from Arizona, she graduated at the top of her high school class and has always aspired to give back to her community. But ultimately, she decided against medical school for one reason: chemistry. It’s not that she isn’t smart enough for chemistry — far from it. She just hates it, finding it dull and unrewarding.
World Pharma News
NOVEMBER 10, 2023
Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug discovery, announced that they have updated the focus of their research collaboration to precision oncology. The oncology-focused collaboration will leverage Bayer's small molecule compound library and expertise in biology and medicinal chemistry as well as Recursion’s purpose-built artificial intelligence-guided drug discovery platform.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Pharma Times
NOVEMBER 10, 2023
The trial is testing whether Mavenclad could benefit upper limb movement in MS patients - News - PharmaTimes
STAT
NOVEMBER 10, 2023
In late August 2017, Hurricane Harvey brought Texas rain that just wouldn’t stop. After four torrential days, 75 people had died, and Houston — America’s fourth largest city — was deep under water. But given that the area is home to Superfund sites , fossil fuel-fired power plants, and other petrochemical hubs, this wasn’t ordinary rainwater.
European Pharmaceutical Review
NOVEMBER 10, 2023
US researchers have developed the Geometric Viability Assay (GVA), which has been shown to be a fast, cheap and sustainable method for counting microorganisms. Since it is 36 times faster than conventional methods, uses 15 times less plastic, and is low cost, Geometric Viability Assay could “replace existing viability assays and enable viability measurements at previously impractical scales”, the paper noted.
STAT
NOVEMBER 10, 2023
WASHINGTON — Doctors are staring down a cut to their Medicare pay next year, and while the news has united them in outrage, it’s also turned one specialty against another. Medicare officials last week announced its major annual update to the way the program pays physicians. Along with other changes, it includes a policy that will boost payments to specialties that rely on evaluating and managing patients, as opposed to those that focus on procedures.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
European Pharmaceutical Review
NOVEMBER 10, 2023
Novo Nordisk has announced plans to invest over 42 billion Danish kroner (nearly £5 billion) starting in 2023, to expand its manufacturing facilities in Kalundborg, Denmark. According to the pharma company , the financing will add to global capacity: from manufacturing of active pharmaceutical ingredients (API) through to packaging. Most of the investment will be focused on API capacity.
STAT
NOVEMBER 10, 2023
LONDON — Two days after similar decisions in the U.S. and U.K. , regulators in Europe on Friday recommended that the approval of Eli Lilly’s diabetes drug Mounjaro be widened to include obesity. The ruling from a committee of the European Medicines Agency now goes to the European Commission, which makes the final decision but almost always follows the EMA’s guidance.
Pharma Times
NOVEMBER 10, 2023
A rare disease is defined as a condition that affects fewer than one in 2,000 people - News - PharmaTimes
STAT
NOVEMBER 10, 2023
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda, so far, is uncertain. We do expect, however, to catch up on our reading, manicure the grounds, and promenade with the official mascots. We may also hope to hold another listening party with Mrs.
The Pharmacist
NOVEMBER 10, 2023
Former pharmacy minister and chair of the health and social care committee (HSCC) Steve Brine has said he ‘doubts very much’ that changes to hub and spoke legislation is the answer to problems faced by independent community pharmacies. At the Sigma Pharmaceuticals UK conference last weekend, Mr Brine described the government’s silence on hub and […] The post Hub and spoke unlikely to solve sector’s problems, says HSCC chair appeared first on The Pharmacist.
STAT
NOVEMBER 10, 2023
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.
European Pharmaceutical Review
NOVEMBER 10, 2023
Bioburden and sterility testing: how to conserve gene therapy product Kathy Zagaroli, Senior Director of Quality Control at Kiniksa Pharmaceuticals, and Tom Bujold, Senior Director of Quality Control at REGENXBIO, discuss the challenges of bioburden and sterility testing for gene therapies and why industry must come together to drive increased harmonisation.
STAT
NOVEMBER 10, 2023
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today we have two FDA approvals, preview late-breakers at this weekend’s American Heart Association scientific sessions, and offer up your very favorite podcast.
Pharmaceutical Technology
NOVEMBER 10, 2023
The US FDA has granted approval for Takeda’s Adzynma for congenital thrombotic thrombocytopenic purpura, a rare blood clotting disorder.
The Thyroid Pharmacist
NOVEMBER 10, 2023
I often get messages from people with Hashimoto’s and other autoimmune diseases, that say: “Thanks for your efforts, but I’ve already tried everything. I have cut out gluten, dairy, and soy from my diet, and still have Hashimoto’s. How can your work help me?” While changing your diet is an incredibly important first step that will greatly help many of you, if you do not see a complete remission of your symptoms within three to six months, I encourage you to dig deeper.
Pharmaceutical Technology
NOVEMBER 10, 2023
AstraZeneca has posted a profit after tax of $1.37bn for Q3 2023 versus $1.64bn in the same quarter of the previous year, a decline of 16%.
European Pharmaceutical Review
NOVEMBER 10, 2023
Exploring the complex pathway of paediatric drug development The formulation development of paediatric medications poses unique challenges compared to that of adult medications. Tom Hegarty, Head of Technical Operations for Almac Pharma Services, delves into some of the key considerations when looking to develop child-friendly formulations. Definitive screening design to accelerate process characterisation Mourad Mellal, Director of Statistics, Product Development at Catalent, elucidates the rol
Drug Patent Watch
NOVEMBER 10, 2023
Acetylcysteine is the generic ingredient in seven branded drugs marketed by Cumberland Pharms, Aspen, Eugia Pharma, Exela Pharma, Fresenius Kabi Usa, Indoco, Rising, Sagent Pharms Inc, Steriscience, Zydus Pharms, Alvogen,… The post New tentative approval for Rising drug acetylcysteine appeared first on DrugPatentWatch - Make Better Decisions.
BioPharma Dive
NOVEMBER 10, 2023
Cargo Therapeutics is the seventh oncology biotech to successfully price an IPO this year.
Drug Channels
NOVEMBER 10, 2023
Today’s guest post comes from James Pisano, Partner, Market Access at The Dedham Group and Dinesh Kabaleeswaran, SVP of Insights & Advisory Teams at MMIT. James and Dinesh offer four trends that they predict will shape medication access in the coming years. Click here to learn about consulting services from MMIT and its sister company The Dedham Group.
Big Molecule Watch
NOVEMBER 10, 2023
Recently, Biogen and Samsung Bioepis’s ranibizumab biosimilar (BYOOVIZ) was granted interchangeable status by the U.S. Food and Drug Administration. BYOOVIZ was deemed interchangeable to Genentech’s LUCENTIS for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and myopic choroidal neovascularization.
Outsourcing Pharma
NOVEMBER 10, 2023
A partnership between clinical research technology company uMotif and cognitive science company, Cogstate Limited, will see the companies continue existing work that includes a major phase 2 clinical trial of a psychedelic therapeutic.
pharmaphorum
NOVEMBER 10, 2023
Bayer pledges up to $1.5bn for Recursion oncology alliance Phil.
Pharmafile
NOVEMBER 10, 2023
Daiichi Sankyo has announced that Vanflyta (quizartinib) has been approved in the EU for combination use with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3-ITD positive. This authorisation makes Vanflyta the first FLT3 inhibitor to be approved by the European […] The post Daiichi Sankyo’s Vanflyta approved by EC for acute myeloid leukaemia treatment appear
pharmaphorum
NOVEMBER 10, 2023
Novo Nordisk sets aside $6bn to boost production capacity Phil.
Outsourcing Pharma
NOVEMBER 10, 2023
Excessive costs cost and time to market in clinical trials could soon be eliminated thanks to the addition of a patient access store (PAS) to Phesi's trial accelerator platform.
pharmaphorum
NOVEMBER 10, 2023
Takeda gets okay in US for rare blood disorder drug Phil.
Outsourcing Pharma
NOVEMBER 10, 2023
The first scientific milestone stemming from a collaboration between Sosei Heptares and Kallyope that was announced last year (2022) has been reached.
Pharmafile
NOVEMBER 10, 2023
Novo Nordisk have announced plans to invest over 42bn Danish kroner to expand its existing manufacturing facilities in Kalundbord, Denmark, for production of the company’s current and future product portfolio within serious chronic diseases. The investment is intended to create additional capacity across its entire value chain from the manufacturing of active pharmaceutical ingredients (API) […] The post Novo Nordisk invests 42bn Danish kroner to expand facilities in Kalundborg, Denmark ap
BioPharma Dive
NOVEMBER 10, 2023
The maker of Wegovy and Ozempic plans to expand production in its home country of Denmark to help meet surging demand for the GLP-1 drugs.
Expert insights. Personalized for you.
363 
Let's personalize your content